These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20881225)

  • 1. The need for modeling and simulation to design clinical investigations in children.
    Jadhav PR; Kern SE
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):121S-129S. PubMed ID: 20881225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
    Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA
    Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Getting the dose right": facts, a blueprint, and encouragements.
    Peck CC; Cross JT
    Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
    [No Abstract]   [Full Text] [Related]  

  • 4. Study design and simulation approach.
    Läer S; Meibohm B
    Handb Exp Pharmacol; 2011; 205():125-48. PubMed ID: 21882109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy.
    Läer S; Barrett JS; Meibohm B
    J Clin Pharmacol; 2009 Aug; 49(8):889-904. PubMed ID: 19531673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.
    Muller PY; Milton M; Lloyd P; Sims J; Brennan FR
    Curr Opin Biotechnol; 2009 Dec; 20(6):722-9. PubMed ID: 19896825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Are children getting the right drugs?].
    Bratlid D
    Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3290-2. PubMed ID: 16327857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.
    Chien JY; Friedrich S; Heathman MA; de Alwis DP; Sinha V
    AAPS J; 2005 Oct; 7(3):E544-59. PubMed ID: 16353932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Family pediatrics: report of the Task Force on the Family.
    Schor EL;
    Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Missing data in model-based pharmacometric applications: points to consider.
    Gastonguay MR; French JL; Heitjan DF; Rogers JA; Ahn JE; Ravva P
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):63S-74S. PubMed ID: 20881220
    [No Abstract]   [Full Text] [Related]  

  • 11. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.
    De Ridder F
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):235-41. PubMed ID: 15733220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethical issues of clinical trials in children: a European perspective.
    Sammons H
    Arch Dis Child; 2009 Jun; 94(6):474-7. PubMed ID: 19208673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.
    Vinks AA; Emoto C; Fukuda T
    Clin Pharmacol Ther; 2015 Sep; 98(3):298-308. PubMed ID: 26073179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of modeling and simulation in pediatric investigation plans.
    Manolis E; Osman TE; Herold R; Koenig F; Tomasi P; Vamvakas S; Saint Raymond A
    Paediatr Anaesth; 2011 Mar; 21(3):214-21. PubMed ID: 21244569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A proof-of-concept clinical trial design combined with dose-ranging exploration.
    Wang X; Ting N
    Pharm Stat; 2012; 11(5):403-9. PubMed ID: 22714951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing simple PK-PD studies in children.
    Thomson AH; Elliott HL
    Paediatr Anaesth; 2011 Mar; 21(3):190-6. PubMed ID: 21040154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visualization concepts to enhance quantitative decision making in drug development.
    Dykstra K; Pugh R; Krause A
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):130S-139S. PubMed ID: 20881226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing paediatric medicines: identifying the needs and recognizing the challenges.
    Ernest TB; Elder DP; Martini LG; Roberts M; Ford JL
    J Pharm Pharmacol; 2007 Aug; 59(8):1043-55. PubMed ID: 17725846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactive visualization and communication for increased impact of pharmacometrics.
    Krause A; Gieschke R
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):140S-145S. PubMed ID: 20881227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolution of legislation to regulate pediatric clinical trials: Present and continuing challenges.
    Gans-Brangs KR; Plourde PV
    Adv Drug Deliv Rev; 2006 Apr; 58(1):106-15. PubMed ID: 16530291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.